In addition to directly influencing satiety and appetite control via hypothalamic and hindbrain pathways, GLP-1RAs appear to engage higher-order networks involved in reward processing and emotional regulation, such as the insula, amygdala, and medial prefrontal cortex
Peptidomimetic regulation of growth hormone secretion
This month's Broker Brief breaks down: - Why up to 65% of GLP-1 users discontinue within a year, and why that turns coverage into a sunk cost for employers - What oral GLP-1s like Lilly's Foundayo mean for demand, when most plans still have eligibility rules written for injectables only - How fast a PBM formulary decision can move, using this year's Zepbound to Wegovy switch and back as the case in point - Why 38% of employers already tie GLP-1 coverage to participation in a lifestyle or behavioral program If you're advising employers on GLP-1 coverage, this is where the conversation is heading
The risk of major cardiovascular events was 18% lower in the semaglutide group than in the placebo group (212 vs
My entire body is sore after class
See below for more information and decide which injection will help you reach your goal
